#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA874428	B	Maximum percent of enhancement of binding.		31		protein complex format	Scientific Literature
2.	ALA633999	B	Maximum percent of inhibition of binding was determined		30		protein complex format	Scientific Literature
3.	ALA634000	B	Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1		4		tissue-based format	Scientific Literature
4.	ALA634001	B	Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-4		6		tissue-based format	Scientific Literature
5.	ALA634002	B	Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-5		5		tissue-based format	Scientific Literature
6.	ALA634003	B	Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-6		8		tissue-based format	Scientific Literature
7.	ALA634004	B	Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-7		1		tissue-based format	Scientific Literature
8.	ALA634005	B	Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-8-10e-4		1		tissue-based format	Scientific Literature
9.	ALA636020	B	Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-9-10e-4		1		tissue-based format	Scientific Literature
10.	ALA636021	B	Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-9-10e-6		1		tissue-based format	Scientific Literature
11.	ALA632851	B	Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-4		1		tissue-based format	Scientific Literature
12.	ALA632852	B	Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-6		1		tissue-based format	Scientific Literature
13.	ALA632853	B	Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 2		29		tissue-based format	Scientific Literature
14.	ALA632854	B	Compound was evaluated for its ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-9-10e-11		1		tissue-based format	Scientific Literature
15.	ALA636099	B	Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 3.		16		tissue-based format	Scientific Literature
16.	ALA636100	B	Compounds was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 4		2		assay format	Scientific Literature
17.	ALA636101	B	Compounds was evaluated in vitro for ability to enhance and inhibit the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-3		1		assay format	Scientific Literature
18.	ALA636102	B	Compounds was evaluated in vitro for ability to enhance and inhibit the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 4		1		assay format	Scientific Literature
19.	ALA639518	B	Compounds was evaluated in vitro for ability to enhance and inhibit the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 5		1		assay format	Scientific Literature
20.	ALA639519	B	Compound was evaluate for its ability to enhance (+/-)-[3H]nicotine binding at a dose range 10e-11 M to 10E-8 M was reported		1		protein complex format	Scientific Literature